US 12,351,641 B2
Production of proteins in glutamine-free cell culture media
Martin Gawlitzek, Redwood City, CA (US); Shun Luo, Irvine, CA (US); and Christina Teresa Bevilacqua, San Ramon, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Nov. 8, 2024, as Appl. No. 18/942,174.
Application 18/942,174 is a continuation of application No. 18/820,925, filed on Aug. 30, 2024.
Application 18/820,925 is a continuation of application No. 17/217,706, filed on Mar. 30, 2021, granted, now 12,103,975, issued on Oct. 1, 2024.
Application 17/217,706 is a continuation of application No. 16/412,791, filed on May 15, 2019, granted, now 10,982,003, issued on Apr. 20, 2021.
Application 16/412,791 is a continuation of application No. 16/138,704, filed on Sep. 21, 2018, abandoned.
Application 16/138,704 is a continuation of application No. 15/881,308, filed on Jan. 26, 2018, abandoned.
Application 15/881,308 is a continuation of application No. 15/623,226, filed on Jun. 14, 2017, abandoned.
Application 15/623,226 is a continuation of application No. 14/670,079, filed on Mar. 26, 2015, granted, now 9,714,293, issued on Jul. 25, 2017.
Application 14/670,079 is a continuation of application No. 13/945,531, filed on Jul. 18, 2013, abandoned.
Application 13/945,531 is a continuation of application No. 12/852,377, filed on Aug. 6, 2010, granted, now 8,512,983, issued on Aug. 20, 2013.
Claims priority of provisional application 61/232,889, filed on Aug. 11, 2009.
Prior Publication US 2025/0066493 A1, Feb. 27, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 14/705 (2006.01); C07K 16/18 (2006.01); C07K 16/22 (2006.01); C12N 5/00 (2006.01)
CPC C07K 16/2878 (2013.01) [C07K 14/70575 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); C12N 5/0018 (2013.01); C12N 5/0043 (2013.01); C07K 2317/14 (2013.01); C07K 2319/30 (2013.01); C12N 2500/32 (2013.01); C12N 2500/33 (2013.01); C12N 2500/90 (2013.01)] 30 Claims
 
16. A process for producing a therapeutic IgG antibody in a Chinese hamster ovary (CHO) host cell expressing said therapeutic IgG antibody, wherein the process comprises culturing the CHO host cell in a production phase culture medium that is essentially free of glutamine, wherein the production phase culture medium comprises asparagine provided at a concentration in the range of 2.5 mM to 15 mM,
wherein the therapeutic IgG antibody is selected from the group consisting of an anti-CD4 antibody, an anti-EGF-like-domain 7 (EGFL7) antibody, an anti-IL13 antibody, an anti-DR5 antibody, an anti-BR3 antibody, an anti-beta 7 integrin subunit antibody, dacetuzumab, an anti-CD20 monoclonal, an anti-MET receptor tyrosine kinase antibody, an anti-neuropilin-1 (NRP1) antibody, an anti-OX40 ligand antibody, an anti-oxidized LDL (oxLDL) antibody, a HER dimerization inhibitor (HDI) antibody, and a rhuMAb IFN alpha antibody.